Ortin Global
NSE: ORTINGLOBE · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Ortin Global's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Ortin Laboratories Ltd is a pharmaceutical company incorporated in 1986 that specialises in the manufacturing and trading of drugs, pharmaceutical formulations, and intermediates. The company also maintains a business interest in the real estate sector.
Business Model
The company generates revenue through the production and sale of pharmaceutical products and by engaging in real estate development activities.
Growth Outlook
Growth is primarily driven by the demand for pharmaceutical formulations and the potential appreciation or development of real estate assets.
Key Risks
- Regulatory Compliance. The pharmaceutical industry is subject to stringent government regulations and quality standards that can impact production and profitability.
- Market Volatility. The company's exposure to the real estate sector introduces risks related to property market cycles and liquidity constraints.
- Competitive Pressure. Intense competition within the pharmaceutical manufacturing sector may exert downward pressure on margins for drug formulations and intermediates.
Start your research today
Unlock AI insights, financials, peers and live data on Ortin Global and 5,000+ companies — free.
Key Metrics
REVENUE
₹0.09 Cr
TTM · standalone
NET PROFIT
₹-0.74 Cr
TTM · standalone
EPS
₹-0.92
TTM · standalone
RETURN ON EQUITY
-41.2%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
-32.3%
TTM · standalone
P/E
-15.8x
Q4 FY26 · standalone
EV/EBITDA
-17.6x
Q4 FY26 · standalone
EBITDA MARGIN
-800.0%
TTM · standalone
NET PROFIT MARGIN
-33.3%
Q4 FY26 · standalone
DEBT TO EQUITY
0.8x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Ortin GlobalORTINGLOBE | ₹12 Cr | -15.78 | -17.60 | -73.5% | -800.0% | -41.2% | -32.3% | +24.7% |
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Q4 FY26
Financials
Ortin Global
NSE: ORTINGLOBE · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Ortin Global's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Ortin Laboratories Ltd is a pharmaceutical company incorporated in 1986 that specialises in the manufacturing and trading of drugs, pharmaceutical formulations, and intermediates. The company also maintains a business interest in the real estate sector.
Business Model
The company generates revenue through the production and sale of pharmaceutical products and by engaging in real estate development activities.
Growth Outlook
Growth is primarily driven by the demand for pharmaceutical formulations and the potential appreciation or development of real estate assets.
Key Risks
- Regulatory Compliance. The pharmaceutical industry is subject to stringent government regulations and quality standards that can impact production and profitability.
- Market Volatility. The company's exposure to the real estate sector introduces risks related to property market cycles and liquidity constraints.
- Competitive Pressure. Intense competition within the pharmaceutical manufacturing sector may exert downward pressure on margins for drug formulations and intermediates.
Start your research today
Unlock AI insights, financials, peers and live data on Ortin Global and 5,000+ companies — free.
Key Metrics
REVENUE
₹0.09 Cr
TTM · standalone
NET PROFIT
₹-0.74 Cr
TTM · standalone
EPS
₹-0.92
TTM · standalone
RETURN ON EQUITY
-41.2%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
-32.3%
TTM · standalone
P/E
-15.8x
Q4 FY26 · standalone
EV/EBITDA
-17.6x
Q4 FY26 · standalone
EBITDA MARGIN
-800.0%
TTM · standalone
NET PROFIT MARGIN
-33.3%
Q4 FY26 · standalone
DEBT TO EQUITY
0.8x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26